Results 11 to 20 of about 72,405 (280)

Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease. [PDF]

open access: yesPLoS ONE, 2018
Overt fibrostenotic disease is a relative contraindication for anti-TNF therapy in Crohn's disease. We hypothesized that subclinical fibrosis may also contribute to an incomplete response to anti-TNF therapy before the onset of symptomatic stenosis.In a ...
Jessica R de Bruyn   +10 more
doaj   +1 more source

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease [PDF]

open access: yes, 2002
: OBJECTIVE: Infliximab is an effective treatment for refractory or fistulizing Crohn's disease (CD). However, about 30% of patients do not respond to infliximab for unknown reasons.
Carbonez, An   +4 more
core   +2 more sources

Development and validation of enzyme-linked immunosorbent assays for the measurement of infliximab and anti-drug antibody levels

open access: yesHeliyon, 2023
Infliximab and its anti-drug antibody (ADA) serum concentrations exhibit a strong correlation with clinical response and loss of response. The use of therapeutic drug monitoring to measure the concentration of infliximab and ADA can facilitate clinical ...
Dong Xiang   +7 more
doaj   +1 more source

Infliximab‐induced seizures in a patient with Crohn’s disease: a case report

open access: yesBMC Gastroenterology, 2021
Background Infliximab-induced seizures in patients with Crohn’s disease are extremely rare and the mechanism of infliximab-induced seizures is unclear.
Zhijie Lv, Xiaoqi Zhang, Li Wu
doaj   +1 more source

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events

open access: yesCurrent Oncology, 2021
Background and aims: Current guidelines state that infliximab is contraindicated for the treatment of immune checkpoint inhibitor-related hepatitis (ir-hepatitis) due to the risk of inducing further liver damage.
Daniel V. Araujo   +8 more
doaj   +1 more source

Safety aspects of infliximab in inflammatory bowel disease patients - A retrospective cohort study in 100 patients of a German University Hospital [PDF]

open access: yes, 2004
Background: Infliximab, a chimeric anti-tumour necrosis factor monoclonal antibody with potent anti-inflammatory effects, represents an effective treatment option in patients with severe inflammatory bowel disease (IBD).
Seiderer, J.   +5 more
core   +1 more source

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

open access: yesBMC Musculoskeletal Disorders, 2011
Background This study in patients with rheumatoid arthritis (RA) treated with infliximab describes prospectively the course of (anti)infliximab levels within an infusioncycle to assess at what moment patients develop low/no infliximab trough levels and ...
van Riel Piet LCM   +6 more
doaj   +1 more source

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

open access: yesBMC Musculoskeletal Disorders, 2012
Background To get insight in the prevalence of high, or low/no serum infliximab trough levels in patients with low disease activity and if serum trough levels are stable and reliable longitudinally we conducted a prospective cohort study Methods In a ...
van der Maas Aatke   +5 more
doaj   +1 more source

Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis.

open access: yesمجلة كلية الطب, 2015
Background: Rheumatoid arthritis is a common chronic and destructive autoimmune arthropathy .Treatment with infliximab gives great improvement to a large numbers of patients with RA ,however, in some patients after prolonged treatment infliximab can ...
Mohammed A. Al-Karkhi   +2 more
doaj   +1 more source

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?

open access: yesFrontiers in Pharmacology, 2020
ObjectiveTo compare the market dynamics of biosimilar infliximab among four Organization for Economic Cooperation and Development (OECD) countries (UK, France, Japan, and Korea) where supply-side and demand-side policies varied greatly, given high and ...
Yujeong Kim   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy